Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. - Wikidata - wikimedia - TriplyDB

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

http://www.wikidata.org/entity/Q33392649

about

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Targeted drugs in small-cell lung cancer Small cell lung cancer (SCLC): no treatment advances in recent years Origins, genetic landscape, and emerging therapies of small cell lung cancer Genomic profiling of small-cell lung cancer: the era of targeted therapies RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.The new concepts on overcoming drug resistance in lung cancer.Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer Chemotherapy for small cell lung cancer: a comprehensive review Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.Expression of phosphorylated mTOR and its clinical significances in small cell lung cancer Small cell lung cancer: will recent progress lead to improved outcomes?Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.Metabolic complications with the use of mTOR inhibitors for cancer therapy Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors The development of targeted therapy in small cell lung cancer.Targeting autophagy during cancer therapy to improve clinical outcomes.Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.The Biological Role of PI3K Pathway in Lung Cancer.Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016.Genomic profiling of high-grade large-cell neuroendocrine carcinoma of the colon.Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.Targeting signaling pathways in lung cancer therapy.Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer.Second-line treatments of small-cell lung cancers.Modulation of Bax and mTOR for Cancer Therapeutics.

P2860

Q24337757-BA254C51-0704-49BC-95EB-8BF9F2A17CE5 Q26767017-6B838203-39A9-43A4-9BB9-67B534996C19 Q26767020-0A65401B-C7FE-44E0-BF8E-FCC8DC839378 Q26798218-320883C6-3249-4F44-857A-5FA2CA71CF73 Q26826915-EE38DDFD-9976-4590-9569-33FD60D06D6A Q27853211-FACA62BD-F148-4385-A6DA-0E9FB036EFA8 Q28071388-7C2AC20A-2304-4030-9150-EBBD00EDEB96 Q30243969-7C17B232-4A72-4E4E-B83A-533A0D40E124 Q30276619-B8F63440-6B8D-4DF2-A871-A17CE1F381B4 Q33409908-76AEDDF0-0C59-4D30-8765-A994F2C56228 Q33422778-7A49B4C8-CCC6-4313-B861-41B6C35782BF Q33754114-55194065-03E9-4ED6-B977-E7F089BBF37E Q34134584-F69EB473-708B-4B7B-9A1F-198758A0EF2A Q34778631-B629F9D2-FCCB-4F81-AE7B-5226D76B7FF2 Q35463464-FAC56711-0184-499B-9C82-A37B0557751D Q35569379-DE9098AE-D8EA-4DF5-A369-A6E5C1CFDBE0 Q35605425-2EE644A7-A925-410F-8B7D-38DEE2931AF6 Q35632245-0F1C6167-8520-416C-8071-E8FDCB47C729 Q35836257-98E1B8E2-2190-40D4-87F0-A124114213B7 Q36035933-54FE913C-1E76-454A-ADA7-99323A1709BC Q36553511-2E840BE8-CBE2-48BD-8757-1AECC68B79DD Q36553517-5ED2B42F-2A0D-4380-BE6C-2B8FBFF1E2DD Q36811784-F62A88F3-EE19-40BE-8AE2-8A383E694BB9 Q36959193-4028DA6D-1498-4C3B-AFE8-07C6E6F76F15 Q37127932-133FADB9-746C-4E65-916D-1C5599B7B6E1 Q37858077-9D074016-6F3F-4B98-8552-EA6CA27EBD5E Q38042638-372761E5-816A-47A1-AC07-00791D49D94F Q38148583-1DCE1F58-5097-41AC-8069-63E6B58D892A Q38166599-51AB3BF4-258E-4C9E-8EE0-0DBAF064DEED Q38371672-4B4083AF-2A86-45C9-ABCF-C16977D52D8C Q38515841-99625072-DF82-4D53-8293-0D664C7CDA46 Q38661479-E0D6D5D2-7CC2-4D3F-863E-F186530C1272 Q38859321-2C91FAA0-9B05-4DFF-B366-E4F550EE7F08 Q39282659-D383D016-B1A2-4585-91BF-555A64C1A527 Q39388106-E5E6EC50-A427-4975-8833-7BF1C3E9EEA3 Q46006150-EFF3529D-1355-4CC7-948A-56B791BB6F15 Q46909057-3887E218-C432-4B22-9499-AC8D3BF3CC2B Q47184289-101D70FD-0F09-49DB-AA17-B9017A386A01 Q47789861-E664C44E-8F5A-43D4-A17B-12FE0EF47C79 Q50662513-B78DAFFD-1FAC-45B6-85C7-DA9437CCBBC9

P2860

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

http://www.wikidata.org/entity/Q33392649

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

@ast

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

@en

type

label

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

@ast

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

@en

prefLabel

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

@ast

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

@en

P1433

Q33392649-C33FF8B5-2624-4ECD-A2A8-6D851890EF6C

P1476

Q33392649-89C046C3-0E69-4003-887E-5800F4D2C645

P2093

Q33392649-01CA2E3A-608B-4F36-9CC1-E8101DD936DC

Q33392649-6C7B3472-6DB6-405A-BEE3-A0DDF7AADABC

Q33392649-8ECB3A3B-1038-4FAD-A026-8C5E3020BBFA

Q33392649-C4E912CA-B4AC-4557-8E61-23342A832C64

Q33392649-DD213D09-026D-4E12-A5BB-140048DC6ACF

Q33392649-E0CA1628-BA4D-4996-A3EA-FEF0BB8C5095

Q33392649-E9C54DF2-94D0-41E0-8140-393F36F25DB0

Q33392649-FFD18F3C-DF7C-416D-AF8F-3E7703F569E7

P304

Q33392649-E3B0D13F-59EE-4BE7-A1E8-13C94A09770B

P31

Q33392649-B1B6B772-DFFB-4657-A581-5A0545C54D13

P356

Q33392649-5E5D4982-A634-407E-9411-904A822809C5

P407

Q33392649-CE5854E4-7D8E-49F6-B205-F2CBF51A6FF6

P433

Q33392649-9386BFDC-87D0-49C0-BA53-1E1369148FB1

P478

Q33392649-C623807F-C035-47DF-9026-940DEDD21C57

P50

Q33392649-F070316F-49F7-4CCA-AD92-225CE1FE41BF

P577

Q33392649-927BC58A-CB2E-48B3-AD4D-2DBFEE956075

P5875

Q33392649-8BCA808B-30F7-4B6A-A6BE-202795254825

P698

Q33392649-54221581-D752-49E1-A654-BAEA8535F461

P356

1078-0432.CCR-10-0802

P1433

Clinical Cancer Research

P1476

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

@en

P2093

Ahmad Tarhini

http://www.w3.org/2001/XMLSchema#string

Athanasios Kotsakis

http://www.w3.org/2001/XMLSchema#string

Athanassios Argiris

http://www.w3.org/2001/XMLSchema#string

Daniel Petro

http://www.w3.org/2001/XMLSchema#string

David Friedland

http://www.w3.org/2001/XMLSchema#string

Sanja Dacic

http://www.w3.org/2001/XMLSchema#string

William Gooding

http://www.w3.org/2001/XMLSchema#string

Yongli Shuai

http://www.w3.org/2001/XMLSchema#string

P304

5900-5907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-0802

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47661014

http://www.w3.org/2001/XMLSchema#string

P698

21045083

http://www.w3.org/2001/XMLSchema#string